Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial

Lymphocytic Leukaemia ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726009690.793538184 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Small Lymphocytic Lymphoma ◽

Phase 3 ◽

Double Blind ◽

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30671-4 ◽

2017 ◽

Vol 18 (3) ◽

pp. 297-311 ◽

Cited By ~ 128

Author(s):

Andrew D Zelenetz ◽

Jacqueline C Barrientos ◽

Jennifer R Brown ◽

Bertrand Coiffier ◽

Julio Delgado ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727253578.793538185 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727253578.793562619 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Lymphocytic Leukaemia ◽

Controlled Trial ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00465-9 ◽

2016 ◽

Vol 17 (2) ◽

pp. 200-211 ◽

Cited By ~ 247

Author(s):

Asher Chanan-Khan ◽

Paula Cramer ◽

Fatih Demirkan ◽

Graeme Fraser ◽

Rodrigo Santucci Silva ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Small Lymphocytic Lymphoma ◽

Phase 3 ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793562618 ◽

2019 ◽

Author(s):

Corrado Girmenia

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30193-1 ◽

2018 ◽

Vol 19 (6) ◽

pp. 799-811 ◽

Cited By ~ 25

Author(s):

Vanesa Gregorc ◽

Rabab M Gaafar ◽

Adolfo Favaretto ◽

Francesco Grossi ◽

Jacek Jassem ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727373020.793538186 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8621 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8621-TPS8621

Author(s):

Myron Stefan Czuczman ◽

Hans Knecht ◽

Rebecca Auer ◽

Joseph James McKendrick ◽

Neil Sun Chua ◽

...

Keyword(s):

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70156-7 ◽

2015 ◽

Vol 16 (6) ◽

pp. 619-629 ◽

Cited By ~ 282

Author(s):

Jin Li ◽

Shukui Qin ◽

Ruihua Xu ◽

Thomas C C Yau ◽

Brigette Ma ◽

...

Keyword(s):

Colorectal Cancer ◽

Supportive Care ◽

Metastatic Colorectal Cancer ◽

Best Supportive Care ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Asian Patients ◽